ÈÈÁÒ×£ºØ | ½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚÖÆÒ©¼¯ÍÅʯɼ¼î¼×»ñµÃÃÀ¹úFDA¡°ÓÐÊý¶ù¿Æ¼²²¡¡±Ò©ÎïÈ϶¨£¡-½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶ £¬£¬£¬£¬£¬ÂȵªÆ½"/> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶ £¬£¬£¬£¬£¬ÂȵªÆ½ ÒøÐÓÒ¶,Þ½ÏãÕýÆøË®,ŵ·úɳÐÇ,ÂȵªÆ½,ÑÎËáÂȱûàº,С¶ùÖ¹¿ÈÌǽ¬,Í·æß¿ËÂå¿ÅÁ£,ºìÂÝÃ¹ËØ¿ÅÁ£,Å£» £»£» £» £» £»ÇËá¿ÅÁ£,Í´¾­Äþ¿ÅÁ£,ÐÂÉú»¯¿ÅÁ£,°¢¹éÑøÑªÌǽ¬,½ðÒø»¨Â¶"/> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶ £¬£¬£¬£¬£¬ÂȵªÆ½"/> ÈÈÁÒ×£ºØ | ½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚÖÆÒ©¼¯ÍÅʯɼ¼î¼×»ñµÃÃÀ¹úFDA¡°ÓÐÊý¶ù¿Æ¼²²¡¡±Ò©ÎïÈ϶¨£¡-½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶ £¬£¬£¬£¬£¬ÂȵªÆ½"/> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶ £¬£¬£¬£¬£¬ÂȵªÆ½ ÒøÐÓÒ¶,Þ½ÏãÕýÆøË®,ŵ·úɳÐÇ,ÂȵªÆ½,ÑÎËáÂȱûàº,С¶ùÖ¹¿ÈÌǽ¬,Í·æß¿ËÂå¿ÅÁ£,ºìÂÝÃ¹ËØ¿ÅÁ£,Å£» £»£» £» £» £»ÇËá¿ÅÁ£,Í´¾­Äþ¿ÅÁ£,ÐÂÉú»¯¿ÅÁ£,°¢¹éÑøÑªÌǽ¬,½ðÒø»¨Â¶"/>

½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú

ͼƬÃû³Æ

ÐÂÎÅ×ÊѶ

ÈÈÁÒ×£ºØ | ½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚÖÆÒ©¼¯ÍÅʯɼ¼î¼×»ñµÃÃÀ¹úFDA¡°ÓÐÊý¶ù¿Æ¼²²¡¡±Ò©ÎïÈ϶¨£¡

ÈÕÆÚ£º

2024Äê05ÔÂ17ÈÕ 15:53


½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú£¨ÒÔϼò³Æ“½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚÖÆÒ©”£©ÓÚ2024Äê5ÔÂ1ÈÕÊÕµ½ÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨ÒÔϼò³Æ“FDA”£©µÄÈ϶¨º¯ £¬£¬£¬£¬£¬¹«Ë¾²úƷʯɼ¼î¼×ÓÃÓÚÖÎÁÆÐÂÉú¶ùȱÑõȱѪÐÔÄÔ²¡£¡£¡£¡£¡£¡£¡£¡£¨HIE£©»ñµÃFDAÊÚÓèµÄ“ÓÐÊý¶ù¿Æ¼²²¡”£¨Rare Pediatric Disease,RPD£©Ò©ÎïÈ϶¨¡£¡£¡£¡£¡£¡£¡£¡£

 

×ʸñÈ϶¨ÇéÐÎ

¹«Ë¾ÓÚ2024Äê3ÔÂÏòFDAÌá½»¹ØÓÚʯɼ¼î¼×RPDÒ©ÎïÈ϶¨µÄÏà¹ØÉêÇë £¬£¬£¬£¬£¬ÉêÇëºÅRPD-2024-812 £¬£¬£¬£¬£¬»ñµÃFDA»Øº¯È·ÈÏ:“ÎÒÃÇÌØ´ËÅú×¼¹ó˾µÄÇëÇó £¬£¬£¬£¬£¬½«ÓÃÓÚÖÎÁÆÐÂÉú¶ùȱÑõȱѪÐÔÄÔ²¡£¡£¡£¡£¡£¡£¡£¡£¨HIE£©µÄʯɼ¼î¼×Ö¸¶¨Îª¡¶Áª°îʳÎï¡¢Ò©Æ·ºÍ»¯×±Æ··¨°¸¡·£¨FD&C·¨°¸£©µÚ529Ìõ(a)(3)£¨21 U.S.C.360ff(a)(4)£©Ëù½ç˵µÄ“ÓÐÊý¶ù¿Æ¼²²¡”Ò©Îï¡£¡£¡£¡£¡£¡£¡£¡£”

 

Ò©Îï»ù±¾ÇéÐÎ

ÐÂÉú¶ù HIE ÊÇÓÉÄÔ×é֯ȱÑõºÍÄÔѪÁ÷Á¿ïÔÌ­ÒýÆðµÄÒ»ÖÖÐÂÉú¶ùÄÔËðÉ˼²²¡ £¬£¬£¬£¬£¬ÏÖÔÚÖÎÁÆ·½·¨°üÀ¨Ö§³ÖÁÆ·¨¡¢¿ØÖƾªØÊ¡¢ÖÎÁÆÄÔË®Öס¢ÑǵÍÎÂÖÎÁƵȡ£¡£¡£¡£¡£¡£¡£¡£

ʯɼ¼î¼×Ö÷Òª×÷ÓûúÀíΪÒÒõ£µ¨¼îõ¥Ã¸ÒÖÖÆ £¬£¬£¬£¬£¬Í¬Ê±¾ßÓп¹Ñס¢¿¹Ñõ»¯Ó¦¼¤ÓëÉñ¾­±£» £»£» £» £» £»¤µÈ×÷Óà £¬£¬£¬£¬£¬ÊÊÓÃÓÚÁ¼ÐÔÓ°ÏóÕϰ­ £¬£¬£¬£¬£¬Ìá¸ß»¼ÕßÖ¸ÏòÓ°Ïó¡¢åÚÏëѧϰ¡¢Í¼Ïñ»ØÒä¡¢ÎÞÒâÒåͼÐÎÔÙÈϼ°ÈËÏñ»ØÒäµÈÄÜÁ¦ £¬£¬£¬£¬£¬¶Ô³Õ´ô»¼ÕߺÍÄÔÆ÷ÖÊÐÔ²¡±äÒýÆðµÄÓ°ÏóÕϰ­ÒàÓиÄÉÆ×÷Óà £¬£¬£¬£¬£¬ÒàÓÃÓÚÖØÖ¢¼¡ÎÞÁ¦µÄÖÎÁÆ¡£¡£¡£¡£¡£¡£¡£¡£

 

»ñµÃÃÀ¹úFDA“ÓÐÊý¶ù¿Æ¼²²¡”Ò©Îï×ʸñÈ϶¨µÄÓ°Ïì

ÏÖÔÚ¹«Ë¾Ê¯É¼¼î¼×ÖÊÁÏÒ©Óëʯɼ¼î¼××¢ÉäÒºÒÑÉÏÊÐÏúÊÛ £¬£¬£¬£¬£¬Ê¯É¼¼î¼×¿ØÊÍÆ¬ÒѽøÈëÁÙ´²ÊÔÑé½×¶Î¡£¡£¡£¡£¡£¡£¡£¡£±¾´Îʯɼ¼î¼×ÖÎÁÆÐÂÉú¶ùȱÑõȱѪÐÔÄÔ²¡Ë³Ó¦Ö¢»ñµÃ FDA“ÓÐÊý¶ù¿Æ¼²²¡”Ò©Îï×ʸñÈ϶¨ £¬£¬£¬£¬£¬¼ÓËÙÁ˹«Ë¾Ò©Æ·¹ú¼Ê»¯Õ½ÂԽṹ¡£¡£¡£¡£¡£¡£¡£¡£FDA ΪÃãÀøÓÐÊý¡¢ÑÏÖØºÍΣ¼°ÉúÃüµÄ¶ù¿ÆÒ©ÎïµÄ¿ª·¢¶øÉèÁ¢µÄ“ÓÐÊý¶ù¿Æ¼²²¡”Ò©Îï×ʸñÈ϶¨ £¬£¬£¬£¬£¬ÎªÓÐÊý¡¢ÑÏÖØµÄ¶ù¿ÆÐÂÒ©¿ª·¢Ìṩ¼¤Àø £¬£¬£¬£¬£¬¹«Ë¾½«Óлú»áÔÚ²úÆ·Ñз¢¡¢×¢²áµÈ·½ÃæÏíÊÜÃÀ¹úµÄÕþ²ßÖ§³Ö £¬£¬£¬£¬£¬°üÀ¨ FDA ¹ØÓÚÁÙ´²¿ª·¢µÄÖ¸µ¼¡£¡£¡£¡£¡£¡£¡£¡£ÈôδÀ´Ê¯É¼¼î¼×ÖÎÁÆÐÂÉú¶ùHIEµÄÐÂÒ©ÉêÇë»ñµÃÅú×¼ £¬£¬£¬£¬£¬ÔòÓлú»áÉêÇë»ñµÃFDAÊÚÓèµÄÓÅÏÈÉóÆÀȯ£¨PriorityReview Voucher,PRV£©¡£¡£¡£¡£¡£¡£¡£¡£ÓÅÏÈÉóÆÀȯ¿ÉÓÃÓÚ¼ÓËÙÆóÒµÆäËû²úÆ·µÄÐÂÒ©ÉêÇëÉóÆÀÀú³Ì £¬£¬£¬£¬£¬Òà¿É³öÊÛתÈøøÆäËûÐÂÒ©ÉÏÊÐÉêÇëÈË £¬£¬£¬£¬£¬¸¶ÓëÊÜÈ÷½²úÆ· FDA ÓÅÏÈÉóÆÀÈ¨Òæ¡£¡£¡£¡£¡£¡£¡£¡£

Ïà¹ØÍÆ¼ö

ÍøÕ¾µØÍ¼